Abstract
Purpose :
To assess safety and efficacy of topically administered 0.4% ripasudil ophthalmic solution (Glanatec®; Kowa Pharmaceuticals), a topical Rho-kinase inhibitor, in dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).
Methods :
Eleven three-year old Beagle dogs with ADAMTS10-OAG (five males and six females) were used. The four-week study included a baseline period (week 1), q24h administration (week 2), q12h administration (week 3), and washout period (week 4). Left and right eyes were randomly assigned to receive either balanced salt solution (BSS) sham or ripasudil treatment. Efficacy assessments consisted of diurnal intraocular pressure (IOP) and pupil diameter measurements. Safety was assessed by diurnal conjunctival hyperemia, routine eye examinations, central corneal thickness, and gonioscopy. The linear Gaussian model was used to evaluate the differences in least square means of quantitative outcome measures between eyes that received BSS and ripasudil.
Results :
There were no significant differences in mean IOPs between ripasudil- and BSS-treated eyes (baseline period: ripasudil 27.9 ± 1.5 mmHg vs. BSS 27.0 ± 1.5 mmHg; q24h-treatment: ripasudil 28.8 ± 1.7 mmHg vs. BSS 27.7 ± 1.7 mmHg; q12h-treatment: ripasudil 30.8 ± 2.8 mmHg vs. BSS 29.7 ± 2.8 mmHg; washout period: 34.7 ± 2.7 mmHg vs. BSS 32.9 ± 2.6 mmHg). There was also no effect on diurnal pupil diameter. Mild to moderate conjunctival hyperemia developed in both ripasudil- and BSS-treated eyes during the treatment periods (weeks 2 & 3). No other adverse effects were observed.
Conclusions :
Due to lack of efficacy, these results do not support future use of ripasudil ophthalmic solution as treatment for canine glaucoma.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.